6533b826fe1ef96bd1283bf9
RESEARCH PRODUCT
Nanohybrid for Photodynamic Therapy and Fluorescence Imaging Tracking without Therapy
María González-béjarJulia Pérez-prietoLaura Francés-sorianoJosé Manuel García-verdugoDmitriy A. PritmovAndrey F. MironovOlga A. FedorovaMarina A. ZakharkoM. A. GrinVicente Herranz-pérezPavel A. Panchenkosubject
Fluorescence-lifetime imaging microscopyMaterials scienceGeneral Chemical Engineeringmedicine.medical_treatmentPhotodynamic therapy02 engineering and technologyGeneral Chemistry010402 general chemistry021001 nanoscience & nanotechnologyTracking (particle physics)Photochemistry01 natural sciencesFluorescencePorphyrinPhoton upconversion0104 chemical scienceschemistry.chemical_compoundchemistryMaterials ChemistrymedicinePhotosensitizer0210 nano-technologyAbsorption (electromagnetic radiation)description
Theranostic upconversion nanoparticles (UCNPs) are ideal candidates for personalized medicine. We present a smart, easy-to-prepare nanohybrid (NH) suitable for NIR-theragnosis and imaging tracking without triggering therapy simultaneously. The photophysical features of each component have been carefully selected in order to maximize the capabilities for theragnosis, in particular, the upconversion emission and the photosensitizer absorption. In addition, NH presents a fluorescent marker with one-photon absorption in the green and two-photon absorption cross-section at NIR wavelengths where the UCNP does not absorb, thus enabling innocuous tracking. Thus, the NH consists of NaYF4:Yb, Er, Tm (UCYbErTm) emitting in the UV, vis, and NIR; a broadband-absorbing natural porphyrin (PP) in the UV-to-NIR range but from 580 to 675 nm; and a 1,8-naphthalimide (NI) with two absorption bands (UV, VIS), and dual emission. In vitro assays demonstrate that UCYbErTm@PP/NI NH is noncytotoxic and extremely effective for NIR-...
year | journal | country | edition | language |
---|---|---|---|---|
2018-05-11 | Chemistry of Materials |